Chronic idiopathic urticaria

This study tested whether analyzing a patient's DNA and RNA could help doctors pick the right drug for inflammatory diseases that don't fit standard categories. 32 adults with at least two affected organs (including skin) received one of six targeted therapies based on their mole…

This phase 2 trial tested an oral drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching lasting months) that standard antihistamines couldn't control. Participants took either povorcitinib or a placebo for 12 weeks to see if the drug reduced…

This Phase 2 trial tested a new injectable drug called LP-003 in 202 adults with chronic spontaneous urticaria (long-lasting hives and itching) that standard antihistamines couldn't control. The study compared LP-003 to a placebo and to an existing drug (omalizumab) to see if it …

This study tested the drug dupilumab (Dupixent) in 15 children aged 2 to 12 who have chronic spontaneous urticaria (CSU), also known as long-lasting hives, that didn't get better with antihistamines. The main goals were to check how the drug behaves in the body and to see if it's…

This study tested a drug called remibrutinib in 144 adults with chronic spontaneous urticaria (hives lasting over 6 months) that standard antihistamines couldn't control. Participants took a 25 mg tablet twice daily for up to 12 weeks. The main goal was to see if the drug affecte…

This completed Phase 3 trial tested whether TEV-45779, a biosimilar of the drug omalizumab (XOLAIR), works as well as the original for people with chronic hives that don't improve with antihistamines. 608 participants received either the biosimilar or XOLAIR. The main goal was to…

This study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…

This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …

This study tests an experimental drug called EVO756 in 160 adults with moderate to severe chronic spontaneous urticaria (CSU), also known as chronic hives. Participants must have had hives for at least 3 months and not gotten enough relief from standard antihistamines. The goal i…

This early-stage trial tested an experimental oral drug called BGB-16673 in 34 adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching. The study was double-blind and placebo-controlled, meaning neither patients nor doctors knew who got t…

This study looked at whether Xolair (omalizumab) is safe and works for Chinese teenagers with chronic spontaneous urticaria (long-term hives and itching) that doesn't get better with standard antihistamines. 55 teens took part, receiving Xolair for 12 weeks, followed by 4 weeks o…

This study tested two different antihistamine treatments in 60 adults with chronic hives (itchy welts that keep coming back). One group took a higher dose of bilastine, the other took a mix of bilastine and levocetirizine. The goal was to see which approach better reduces itching…

This study tested a drug called ligelizumab in 49 teenagers aged 12 to 17 who had chronic hives (itchy welts) that didn't get better with standard allergy pills. The goal was to see if adding ligelizumab to their current treatment could reduce the number and severity of hives. Pa…

This completed study looked at how the social networks of caregivers affect their stress and health when caring for someone with an inherited disease. Researchers surveyed over 680 participants, including family members and formal caregivers, to understand caregiving burden and s…

This early-stage study tests a new oral drug called HRS-3095 in 66 healthy adults aged 18-55. The main goal is to check safety and how the body processes the drug, not to treat any disease. Results will help design future studies for chronic spontaneous urticaria (long-term hives…

This study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…

This study looked at how often doctors increase the dose or give Xolair more frequently for people with chronic hives. Researchers followed 163 adults for 3 months to see how many needed a stronger treatment plan. The goal was to understand real-world use, not to test a new drug.

This study tested the safety and tolerability of a new biologic drug called LP-003 in 60 healthy volunteers. The drug is being developed for chronic spontaneous urticaria (long-lasting hives). The trial gave single or multiple doses of LP-003 or a placebo by IV to see how the bod…

This completed study took blood samples from 10 people with chronic spontaneous urticaria (long-lasting hives) to check for viral particles. The goal was to see if hidden viruses might be involved in causing the condition. Because it is a small observational study, it can only su…